Full Breakdown
Supreme Court Upholds Medicare Drug-Price Negotiation Program
5/18/2026, 10:59:00 PM
Court Decision Affirms Government Negotiation Authority
On Monday, May 18, 2026, the Supreme Court rejected appeals by pharmaceutical manufacturers challenging the federal government’s authority to negotiate Medicare drug prices. The justices declined to comment, leaving the Third Circuit Court of Appeals’ Philadelphia ruling that dismissed the manufacturers’ claims intact. The decision keeps the Inflation Reduction Act’s negotiation program fully operational.
Legislative Origin and Program Mechanics
The negotiation framework was created by the 2022 Inflation Reduction Act, signed by President Joe Biden. The statute requires the federal government to annually negotiate price reductions for high-cost drugs covered by Medicare, with the first contracts set to begin in 2026. The law provides no expiration date for the program.
Principal Stakeholders
The primary actors are the Supreme Court, the Third Circuit Court of Appeals, the federal administration managing Medicare, and the pharmaceutical companies selling the targeted drugs. Republican lawmakers have publicly opposed the program, while Medicare beneficiaries could see lower out-of-pocket costs.
Scope of Negotiated Drugs and Program Timeline
The government has secured negotiated prices for 25 Medicare drugs, including the GLP-1 treatments Ozempic, Rybelsus and Wegovy. In January 2026, the administration announced a third round of negotiations that would raise the list to 40 drugs before the next annual cycle.
Official Responses from the Judiciary and Administration
The justices did not comment and left the Third Circuit Court of Appeals’ ruling intact, preserving the negotiation authority. Administration officials stress that, without a judicial reversal, halting the program would require congressional action. They present the negotiations as a way to lower drug costs for seniors.
Industry and Political Opposition
Pharmaceutical manufacturers argue that price cuts should focus on insurers and pharmacy-benefit managers, warning that direct government negotiation could hinder innovation. Republican legislators label the program an overreach, noting that no Republican voted for the Inflation Reduction Act and calling the negotiations contrary to free-market principles.
Significance for Medicare Beneficiaries and Health Policy
The negotiation program is intended to lower out-of-pocket costs for Medicare beneficiaries and reduce overall federal health spending on high-cost drugs. The administration frames the effort as a means to make prescription medicines more affordable for seniors.
Unresolved Issues and Potential Legislative Challenges
The Court’s ruling preserves the status quo, but the program’s future depends on Congress, since the statute lacks a termination provision. Sources report no factual contradictions, yet the missing end date leaves open the possibility of legislative amendment or repeal of the negotiation authority.
Future Implementation and Next Steps
The 25 negotiated agreements will be implemented in 2026, and the third round aims to add 15 more drugs, bringing the total to 40. Stakeholders will watch effects on Medicare spending and drug pricing, while Congress may consider legislation to reinforce or adjust the negotiation framework.
